International immunopharmacology
Adjuvant bacillus Calmette-Guérin (BCG) immunotherapy versus BCG combined with disitamab vedotin in BCG-naïve high-risk non-muscle invasive bladder cancer with HER2 expression: A real-world study.
Tianyuan Xu, Keyi Wang, Yifan Chen, Yang Yu, Wentao Zhang, Danjing Shen, Jingcheng Zhang, Jiang Geng, Bo Peng, Yang Yan, Xudong Yao
Published: 202610.1016/j.intimp.2026.116186
Abstract
OBJECTIVE: Recurrence is not rare for high-risk non-muscle invasive bladder cancer (HR-NMIBC) after bacillus Calmette-Guérin (BCG) immunotherapy. We aimed to introduce disitamab vedotin (DV) to BCG and evaluate its efficacy. METHODS: Consecutive BCG-…
Preview only. Read the full abstract at the source